MM-302 is a novel antibody-drug conjugated liposomal doxorubicin that specifically targets cancer cells overexpressing the HER2 receptor. As a liposomal encapsulation of doxorubicin, MM-302 is designed to allow for the selective uptake of drug into tumor cells while limiting exposure to healthy tissues, such as those of the heart.
Unlike other HER2-targeted agents, MM-302 is not designed to inhibit HER2 signaling pathways and relies on HER2 as a means to identify and gain access to the cancer cells. Once inside the cancer cell, the liposome breaks down and releases doxorubicin inside the cell, promoting cell death.
MM-302 in the Clinic
Currently, MM-302 is being evaluated in clinical trials for its ability to treat HER2-positive tumors in both the HERMIONE study for advanced metastatic HER2-positive breast cancer and an ongoing Phase 1 study. Based on our research, future clinical studies may explore MM-302’s potential in other types of HER2+ cancers, tumors with leaky vasculatures and in combination with other agents.
Our research also suggests an opportunity to develop MM-302 in HER2-positive cancers in conjunction with an imaging diagnostic, which would aid in identifying patients who would most likely benefit from this therapy. In previous studies we have incorporated a radioactive label into MM-302 and used this as a means to measure its tumor accumulation.
CLICK HERE to learn more about MM-302 in the Clinic